Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tryton begins trial of side branch stent

This article was originally published in Clinica

Executive Summary

Tryton Medical, of Durham, North Carolina, has initiated a registry study of its Tryton side branch stent. Called E-Tryton 150, the study is one of four registries in Europe evaluating the Tryton device in real-world clinical settings. It will enrol 150 patients with a primary endpoint of overall rate of major adverse cardiac events (MACE) – defined as cardiac death, myocardial infarction and target lesion revascularisation (main and/or side branch) – at six months following the procedure. The study will also assess the technical and procedural success of the stent. Designed to treat bifurcated atherosclerotic lesions, the cobalt chromium Tryton side branch stent is used in conjunction with a conventional drug-eluting stent. It was CE marked in February 2008.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel